Tag: Secondary Hyperparathyroidism

Amgen’s Parsabiv gets EC approval for treating SHPT

pharmanewsdaily- November 13, 2016

American biopharma company Amgen’s Parsabiv drug has been approved by the European Commission for treating secondary hyperparathyroidism. Secondary Hyperparathyroidism (sHPT) is a serious and chronic ... Read More